#1
|
|||
|
|||
Ýíäîêðèíîëîãèÿ
Ýíäîêðèíîëîãèÿ
|
#2
|
|||
|
|||
Îáíîâëåííàÿ ôîðìóëèðîâêà êðèòåðèåâ "Ìåòàáîëè÷åñêîãî ñèíäðîìà" îò Ìåæäóíàðîäíîé ôåäåðàöèè äèàáåòà (àïðåëü 2005):
The metabolic syndrome, which includes diabetes or prediabetes, abdominal obesity, unfavorable lipid profile and hypertension, triples the risk of myocardial infarction or stroke and doubles mortality from these conditions. It also increases the risk of developing type 2 diabetes, if not already present, fivefold. Recent data from Australia and the U.S. suggest that up to one quarter of the adult population may have the metabolic syndrome. The new diagnostic criteria are central obesity, defined as waist equal to or more than 94 cm for males and 80 cm for females in Europids, and ethnic-specific levels in Chinese, Japanese and South Asians; together with two of the following: raised triglycerides of at least 1.7 mmol/L or 150 mg/dL; low HDL-cholesterol, defined as less than 1.04 mmol/L (40 mg/dL) in males and less than 1.29 mmol/L (50 mg/dL) in females; raised blood pressure of at least 130/85 mm Hg; fasting hyperglycemia, defined as glucose equal to or greater than 5.6 mmol/L (100mg/dL) or previous diagnosis of diabetes or impaired glucose tolerance. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ðàöèîíàëüíûé áàçèñ äëÿ ñîçäàíèÿ íîâûõ êðèòåðèåâ: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] __________________ Èñêðåííå, Âàäèì Âàëåðüåâè÷. îáíîâèòü |
#3
|
|||
|
|||
Îò ßíû Ñòóäåíöîâîé
The ‘Edmonton’ Protocol [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] îáíîâèòü [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] îáíîâèòü [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#4
|
|||
|
|||
Ðåñóðñû äëÿ ñïåöèàëèñòîâ è ïàöèåíòîâ ïî äèàáåòó
Äèàáåò â Âåëèêîáðèòàíèè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] University of Massachusetts Diabetes Division [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] It's a New Day In Diabetes [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#5
|
||||
|
||||
Àññîöèàöèÿ ïàöèåíòîâ ñ çàáîëåâàíèÿìè ãèïîôèçà ( Âåëèêîáðèòàíèÿ)
The Pituitary Foundation [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ã.À. Ìåëüíè÷åíêî |
#6
|
||||
|
||||
THYROID DISEASE MANAGER © offers an up-to-date analysis of thyrotoxicosis, hypothyroidism, thyroid nodules and cancer, thyroiditis, and all aspects of human thyroid disease and thyroid physiology. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#7
|
|||
|
|||
THE OFFICIAL WEB SITE FOR THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
|
#8
|
|||
|
|||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Æóðíàë Diabetes Care Åñòü ðàçäåë Clinical Practice Recommendations |
#9
|
||||
|
||||
Menopause
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#10
|
||||
|
||||
Clinical Endocrinology
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#11
|
||||
|
||||
Beata Bartes, ÷ëåí ÒFI ( ìåæäóíàðîäíàÿ àññîöèàöèÿ ïàöèåíòîâ ñ çàáîëåâàíèÿìè ùèòîâèäíîé æåëåçû)
ÿâëÿåòñÿ àâòîðîì áþëëåòåíÿ "Vivre sans Thyroide" (äëÿ ïàöèåíòîâ ñ ãèïîòèðîçîì, â òîì ÷èñëå îïåðèðîâàííûõ ïî ïîâîäó ðàêà ùèòîâèäèíîé æåëåçû) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ýòà æåíùèíà, ñàìà ïåðåíåñøàÿ òèðîèäýêòîìèþ ïî ïîâîäó ðàêà, âûñîêî îöåíèâàåò òàêæå ôîðóì [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (íåìåöêîÿçû÷íûé)
__________________
Ã.À. Ìåëüíè÷åíêî |
#12
|
||||
|
||||
Áðîøþðû äëÿ ïàöèåíòîâ ñ çàáîëåâàíèÿìè Ù.Ç.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#13
|
|||
|
|||
the Society for Behavioral Neuroendocrinology
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#14
|
||||
|
||||
Âûøåë íîâûé íîìåð Th. Internftional (Â. Ôàäååâ ïî ñåêðåòó ïðèçíàëñÿ. ÷òî óæå íà÷àë ïåðåâîäèòü), íî ÿ â êà÷åñòâå àíîíñà.
Íîìåð ïîñâÿùåí ò.í.TSH-receptor disoders (ÿ î÷åíü ëþáëþ òàêèå èíòåëëåêòóàëüíî ÿðêèå èäåè), è îïèñûâàåò 8 êëèíè÷åñêèõ ôåíîòèïîâ ðàçëè÷íûõ ìóòàöèé ýòîãî ðåöåïòîðà. À çäåñü ýòà èíôîðìàöèÿ ïîòîìó, ÷òî åñòü áàçà äàííûõ (comprehensive & up-to-date, ïî çàâåðåíèþ àâòîðîâ) ïî íàøåìó ðîäíîìó, èç ïî÷òåííîãî ñåìåéñòâà G-ñâÿçàííûõ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ã.À. Ìåëüíè÷åíêî |
#15
|
||||
|
||||
A systematic review of drug therapy for Graves’ hyperthyroidism [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|